Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
04:01pm, Monday, 01'st Dec 2025
Approval underscores Amneal's advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWI
Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?
05:49pm, Friday, 28'th Nov 2025
Westshore Wealth initiated 1,381,910 shares in Amneal Pharmaceuticals, a position value increase of $13.83 million. The transaction accounted for 4.73% of Westshore's 13F reportable assets under manag
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
12:00pm, Friday, 28'th Nov 2025
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs
12:24pm, Friday, 21'st Nov 2025
The option-exercise sale represented a notable amount of Shah's overall holdings. Nevertheless, the executive's remaining stake—about 146,000 shares—still represents meaningful exposure.
Amneal Receives U.S. FDA Approval for Iohexol Injection
04:01pm, Thursday, 13'th Nov 2025
BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has app
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript
12:56pm, Thursday, 30'th Oct 2025
Amneal Pharmaceuticals, Inc. ( AMRX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Anthony DiMeo - Head of Investor Relations Chirag Patel - Co-Founder, Co-CEO, President &
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
10:35am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
08:16am, Thursday, 30'th Oct 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.16 per share a year ago.
Amneal Reports Third Quarter 2025 Financial Results
06:00am, Thursday, 30'th Oct 2025
‒ Q3 2025 Net Revenue of $785 million ; GAAP Net Income of $2 million ; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million ; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
04:05pm, Wednesday, 29'th Oct 2025
BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively a
BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroerg
Allspring Global Investments Holdings LLC Buys 13,187 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX
03:47am, Friday, 24'th Oct 2025
Allspring Global Investments Holdings LLC boosted its stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ: AMRX) by 21.8% during the undefined quarter, according to its most recent Form 13F filing with the
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
11:05am, Thursday, 23'rd Oct 2025
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
10:41am, Tuesday, 07'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
09:11am, Monday, 06'th Oct 2025
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
